Hepatic trisegmentectomy for 29 patients with huge liver neoplasms.
OBJECTIVE
To evaluate retrospectively the feasibility and effect of hepatic trisegmentectomy in therapy of huge neoplasms of the liver.


METHODS
From July 1993 to October 1999, 29 patients with huge hepatic neoplasms underwent hepatic trisegmentectomy. Of these, 23 patients suffered from primary liver cancer, 1 hepatic infiltration of gallbladder cancer, 1 metastasis of colon cancer, 1 hepatic angiosarcoma, 1 hepatic neurofibroma, and 2 huge liver cysts. Twenty-six patients were subjected to right trisegmentectomy and the rest 3 left trisegmentectomy. All trisegmentectomies were performed under normothermic interruption of the porta hepatis at single time and these interruptions lasted 15 to 40 minutes.


RESULTS
The relatively good effect was seen in our series. The 1-, 3-, 5-year survival rates for primary liver cancer patients were 63.6%, 36.4% and 27.3%, respectively. The survival period for the patients with hepatic infiltration of gallbladder cancer and liver metastasis of colon cancer was 6 months. Those with hepatic angiosarcoma, hepatic neurofibroma and huge liver cysts have been surviving 35, 26, 25 and 40 months, respectively. Major complications were noted in 5 patients, and one (3.4%, 1/29) died.


CONCLUSIONS
Hepatic trisegmentectomy is safe and effective in treatment of huge hepatic neoplasms if its indications and operative techniques are properly mastered.
Rui
Jing-An
JA
Liver Cancer Institute, Post & Telecom General Hospital, Department of Liver Surgery, 8th Clinical Hospital, Peking University, Beijing 100032, China. rlzhou@mail.bjmu.edu.cn
Zhou
Li
L
Wang
Shao-Bin
SB
Chen
Shu-Guang
SG
Wei
Xue
X
Han
Kai
K
Zhang
Ning
N
Zhao
Hai-Tao
HT
Yang
Xin
X
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003110:Colonic Neoplasms / Q000473:pathology; D003560:Cysts / Q000601:surgery; D005260:Female; D005706:Gallbladder Neoplasms / Q000473:pathology; D006394:Hemangiosarcoma / Q000601:surgery; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009455:Neurofibroma / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome